A$2.62 -0.0 -1.5%
Last Trade - 12:40am
| Market Cap | ÂŁ992.9m |
| Enterprise Value | ÂŁ992.0m |
| Revenue | ÂŁ12.5m |
| Position in Universe | 217th / 1842 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.14 | 3.47 | 3.76 | 5.99 | 13.7 | 22.2 | 36.5 | 66.7 | +175.1% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Polynovo Ltd is an Australia-based medical device company. The Company designs, develops and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. Its development program covers Breast Sling, Hernia and Orthopedic application. NovoSorb is a family of proprietary medical grade polymers that can be utilized to manufacture novel medical devices designed to support tissue repair and which then bio reabsorb in a defined fashion in-situ to harmless by-products. It manufactures NovoSorb polymer devices with the ability to elute drugs, antimicrobials as well as be expressed in a variety of physical formats, including films, foam, coatings/sprays, fibers, plastic structures and biological carrier. Its NovoSorb Biodegradable Temporising Matrix (BTM) is used in a fully debrided clean surgical wound to physiologically close the wound.
| Last Annual | June 30th, 2020 |
| Last Interim | June 30th, 2020 |
| Incorporated | August 12, 1998 |
| Public Since | November 26, 1998 |
| No. of Shareholders: | 20,708 |
| No. of Employees: | 78 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | S&P/ASX All Ordinaries , S&P/ASX 200 , S&P/ASX 300 , ASX Small Ordinaries , |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 661,088,402 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | U 2 320 Lorimer St, MELBOURNE, 3207, Australia |
| Web | http://polynovo.com.au/ |
| Phone | +61 3 86814050 |
| Contact | () |
| Auditors | Ernst & Young |
As of 12:40am, shares in Polynovo are trading at A$2.62, giving the company a market capitalisation of ÂŁ992.9m. This share price information is delayed by 15 minutes.
Shares in Polynovo are currently trading at A$2.62 and the price has moved by 4.31% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Polynovo price has moved by 6.23% over the past year.
Of the analysts with advisory recommendations for Polynovo, there are there are currently 1 "buy" , 2 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Polynovo is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Polynovo is scheduled to issue upcoming financial results on the following dates:
Polynovo does not currently pay a dividend.
Polynovo does not currently pay a dividend.
Polynovo does not currently pay a dividend.
To buy shares in Polynovo you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Polynovo are currently trading at A$2.62, giving the company a market capitalisation of ÂŁ992.9m.
Here are the trading details for Polynovo:
Based on an overall assessment of its quality, value and momentum, Polynovo is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Polynovo are currently priced at A$2.62. At that level they are trading at 12.44% discount to the analyst consensus target price of 0.00.
Analysts covering Polynovo currently have a consensus Earnings Per Share (EPS) forecast of -0.003 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Polynovo. Over the past six months, the relative strength of its shares against the market has been 4.47%. At the current price of A$2.62, shares in Polynovo are trading at 2.07% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Polynovo.
Polynovo's management team is headed by:
Here are the top five shareholders of Polynovo based on the size of their shareholding:
